The Science of Therapeutic Peptides · Volume II
Metabolic, Incretin & Energy
Incretins, GLP-1 medicines, and the biology of weight and energy.
11 chapters
- II.1AOD‑9604A fragment of a hormone, cut to keep the fat loss and drop the rest
- II.2CagrilintideA hormone found as a disease, and rebuilt as a drug
- II.3EloralintideThe second hormone the pancreas sends after a meal, and the analogue built to leave the bone receptor alone
- II.4InsulinThe first peptide medicine, the analogue family that followed, and the standard every later peptide is measured against
- II.5MazdutideThe drug that put the second hormone back in — a GLP-1/glucagon dual agonist, and the first of its kind approved anywhere
- II.6OrforglipronA small molecule at a receptor built for a peptide
- II.7RetatrutideOne peptide, three hormone receptors, and the furthest that drug-induced weight loss has yet been taken
- II.8SemaglutideThe molecule that was made worse at its job, and what followed
- II.9SurvodutideA glucagon-receptor / GLP-1-receptor dual agonist (BI 456906) — discovery, mechanism, and the human record
- II.10TirzepatideThe drug built on a hormone that had already failed — and the outcome trial that did not follow the weight loss
- II.11UltratrutideAn advanced quad-agonist metabolic peptide (GLP-1 / GIP / glucagon / ghrelin) — claimed design, receptor biology, and the evidence gap